REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
Executive Summary
Sen. Leahy's reintroduced CREATES Act allows generic sponsors to sue innovators who fail to provide sufficient quantities of REMS covered products, but seems to give wide latitude to courts; bill reflects Congress' broader focus on generic drugs to address drug pricing issue.
You may also be interested in...
Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers
New draft guidances are an attempt to curb abuse of REMS single shared system process to delay generic entry.
Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers
New draft guidances are an attempt to curb abuse of REMS single shared system process to delay generic entry.
REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
Other sponsors could be using tactics other than REMS abuse to game the system, US FDA Commissioner Scott Gottlieb says.